EHA Library - The official digital education library of European Hematology Association (EHA)

PREVALENCE OF LYMPHOPROLIFERATIVE DISEASES IN PATIENTS WITH AUTOIMMUNE DISORDERS
Author(s): ,
Vladislava Djurasinovic
Affiliations:
Institute of hematology,Belgrade,Serbia
,
Predrag Djuradjevic
Affiliations:
Clinical center Kragujevac,Kragujevac,Serbia;Medicall faculty, University of Kragujevacdic,Kragujevac,Serbia
,
Darko Antic
Affiliations:
Institute of hematology,Belgrade,Serbia;Medical faculty University of Belgrade,Belgrade,Serbia
,
Boško Andjelic
Affiliations:
Institute of hematology,Belgrade,Serbia;Medical faculty University of Belgrade,Belgrade,Serbia
,
Aleksandra Sretenovic
Affiliations:
Institute of hematology,Belgrade,Serbia
,
Vojin Vukovic
Affiliations:
Institute of hematology,Belgrade,Serbia
,
Jelena Bila
Affiliations:
Institute of hematology,Belgrade,Serbia;Medical faculty University of Belgrade,Belgrade,Serbia
,
Jelena jeličić
Affiliations:
Institute of hematology,Belgrade,Serbia
,
Milena Todorovic-Balint
Affiliations:
Institute of hematology,Belgrade,Serbia;Medical faculty University of Belgrade,Belgrade,Serbia
Biljana Mihaljevic
Affiliations:
Institute of hematology,Belgrade,Serbia;Medical faculty University of Belgrade,Belgrade,Serbia
(Abstract release date: 05/19/16) EHA Library. Djurasinovic V. 06/09/16; 134646; PB1746
Dr. Vladislava Djurasinovic
Dr. Vladislava Djurasinovic
Contributions
Abstract
Abstract: PB1746

Type: Publication Only

Background
Lymphoproliferative disorders can be found in patients with previously diagnosed autoimmune disorder.

Aims
We have evaluated type of lymphproliferative disease in population of pts with autoimmune disorders and differences between genders.

Methods
Data from national registry for lymphoproliferative diseases were analysed. From 1992-2015. there was 45pts, male 9(20%) and female 36(80%), median age  57(33-76)years.

Results
42(93%) of pts previously had autoimmune disesase with average 7,63(0,7-27) years. There were: systemic lupus erythematosus (SLE) 22/36(61%), reumathoid arthritis (RA) 8/36 (22%)  and systemic sclerosis (SS) 6/36(17%) in women and   SS 5/9 ( 56%), SLE 2/9(22%), RA 1/9(11%), polimiozitis 1/9(11%) in men.40(89%)pts had non Hodgkin lymphoma (NHL), multiple myeloma (MM) 3(7%) and Hodgkin lymphoma 2(4%). In NHL group 20 were DLBCL, indolent 18- NHL foll. and 2 very agressive.   

Conclusion
The most frequent autoimmune disorder was SLE in women and SS in men.NHL DLBCL was  the most common lymphorpoliferative disease. Pts with these condiotions had higher stage of disease at the diagnosis and there was no difference in survival between male and female pts.

Session topic: E-poster

Keyword(s): Autoimmune disease, B cell lymphoma
Abstract: PB1746

Type: Publication Only

Background
Lymphoproliferative disorders can be found in patients with previously diagnosed autoimmune disorder.

Aims
We have evaluated type of lymphproliferative disease in population of pts with autoimmune disorders and differences between genders.

Methods
Data from national registry for lymphoproliferative diseases were analysed. From 1992-2015. there was 45pts, male 9(20%) and female 36(80%), median age  57(33-76)years.

Results
42(93%) of pts previously had autoimmune disesase with average 7,63(0,7-27) years. There were: systemic lupus erythematosus (SLE) 22/36(61%), reumathoid arthritis (RA) 8/36 (22%)  and systemic sclerosis (SS) 6/36(17%) in women and   SS 5/9 ( 56%), SLE 2/9(22%), RA 1/9(11%), polimiozitis 1/9(11%) in men.40(89%)pts had non Hodgkin lymphoma (NHL), multiple myeloma (MM) 3(7%) and Hodgkin lymphoma 2(4%). In NHL group 20 were DLBCL, indolent 18- NHL foll. and 2 very agressive.   

Conclusion
The most frequent autoimmune disorder was SLE in women and SS in men.NHL DLBCL was  the most common lymphorpoliferative disease. Pts with these condiotions had higher stage of disease at the diagnosis and there was no difference in survival between male and female pts.

Session topic: E-poster

Keyword(s): Autoimmune disease, B cell lymphoma

By clicking “Accept Terms & all Cookies” or by continuing to browse, you agree to the storing of third-party cookies on your device to enhance your user experience and agree to the user terms and conditions of this learning management system (LMS).

Cookie Settings
Accept Terms & all Cookies